KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $5.0 million.

  • Rigel Pharmaceuticals' Change in Accured Expenses fell 88.51% to $789,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 121.03%. This contributed to the annual value of $5.0 million for FY2024, which is 533.97% up from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Change in Accured Expenses is $5.0 million, which was up 533.97% from -$1.2 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Change in Accured Expenses high stood at $5.0 million for FY2024, and its period low was -$4.5 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is -$231,333, with a median of -$1.2 million in 2023.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Change in Accured Expenses tumbled by 513.30% in 2022, and later spiked by 533.97% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Change in Accured Expenses stood at $1.3 million in 2020, then fell by 16.69% to $1.1 million in 2021, then crashed by 513.30% to -$4.5 million in 2022, then soared by 74.64% to -$1.2 million in 2023, then skyrocketed by 533.97% to $5.0 million in 2024.